Proactiveinvestors Australia Redx Pharma Plc Proactiveinvestors Australia Redx Pharma Plc RSS feed en Mon, 24 Jun 2019 23:34:56 +1000 Genera CMS (Proactiveinvestors) (Proactiveinvestors) <![CDATA[RNS press release - Interim Results for six months ended 31 March 2019 ]]> Mon, 10 Jun 2019 16:01:03 +1000 <![CDATA[RNS press release - Short-term Debt Funding Secured ]]> Mon, 10 Jun 2019 16:00:05 +1000 <![CDATA[RNS press release - Update on Plans to Strengthen Balance Sheet ]]> Fri, 03 May 2019 20:34:52 +1000 <![CDATA[RNS press release - Redx to present two posters at AACR 2019 ]]> Fri, 29 Mar 2019 18:00:09 +1100 <![CDATA[RNS press release - Issue of Warrants and Change to Lease Agreement ]]> Thu, 28 Feb 2019 18:00:08 +1100 <![CDATA[RNS press release - Directorate Update ]]> Thu, 14 Feb 2019 18:00:11 +1100 <![CDATA[RNS press release - New in vivo data on ROCK2 ]]> Tue, 12 Feb 2019 18:00:04 +1100 <![CDATA[RNS press release - Receipt of Outstanding Loan ]]> Wed, 06 Feb 2019 22:25:31 +1100 <![CDATA[RNS press release - Deinove return rights to Redx Programme ]]> Thu, 31 Jan 2019 18:00:02 +1100 <![CDATA[RNS press release - Results of Annual General Meeting ]]> Wed, 23 Jan 2019 22:25:18 +1100 <![CDATA[RNS press release - RXC004 Trial Approval ]]> Mon, 21 Jan 2019 18:00:06 +1100 <![CDATA[RNS press release - Second Price Monitoring Extn ]]> Fri, 11 Jan 2019 01:05:56 +1100 <![CDATA[RNS press release - Price Monitoring Extension ]]> Fri, 11 Jan 2019 01:00:49 +1100 <![CDATA[RNS press release - Redx to present at 2019 Biotech Showcase event ]]> Thu, 03 Jan 2019 18:00:11 +1100 <![CDATA[RNS press release - Publication of Annual Report and Accounts ]]> Fri, 28 Dec 2018 22:47:55 +1100 <![CDATA[RNS press release - First RXC006 data for treatment of fibrosis ]]> Fri, 30 Nov 2018 18:00:04 +1100 <![CDATA[RNS press release - Preliminary Results for year ended 30 Sept 2018 ]]> Mon, 19 Nov 2018 18:00:06 +1100 <![CDATA[RNS press release - Redx announces new drug development candidate ]]> Wed, 14 Nov 2018 18:00:02 +1100 <![CDATA[RNS press release - Preclinical data presented at cancer conference ]]> Mon, 05 Nov 2018 18:00:06 +1100 <![CDATA[RNS press release - Notice of Results ]]> Wed, 31 Oct 2018 18:00:07 +1100 <![CDATA[RNS press release - Redx notes election of Lisa Anson to UK BIA BOD ]]> Mon, 29 Oct 2018 18:00:08 +1100 <![CDATA[RNS press release - Details from Redx ROCK2 inhibitor poster ]]> Fri, 26 Oct 2018 17:00:02 +1100 <![CDATA[RNS press release - Redx ROCK2 inhibitors poster to be presented ]]> Mon, 22 Oct 2018 17:00:08 +1100 <![CDATA[RNS press release - Redx Pharma Announces Way Forward For RXC004 ]]> Tue, 04 Sep 2018 16:00:05 +1000 <![CDATA[Media files - New Redx CEO bringing leadership and skills to 'capitalise on its great science' ]]> Wed, 18 Jul 2018 16:13:00 +1000 <![CDATA[News - Redx Pharma looks for some Porcupine help in its fight against cancer and fibrosis ]]> It has been a rough 18 months or so for Redx Pharma PLC (LON:REDX), the AIM-quoted biotech which specialises in developing cancer and fibrosis-fighting drugs.

The company fell into administration last May when Liverpool City Council called in a £2mln loan. Unlike most though, Redx was out again within a few months, having sold off its BTK inhibitor technology and drug development programme to a Nasdaq-listed Loxo Oncology for the princely sum of £30mln (US$40mln).

With the dust settling and shares back to trading on AIM, the drug developer brought in an industry heavyweight in the form of Lisa Anson, who took the reins in June.

READ: Redx shares surge as AstraZeneca's UK boss appointed new CEO

Anson was the president of AstraZeneca PLC’s (LON:AZN) UK division immediately prior to joining Redx, while she also held various other senior leadership roles during her 20-year career at the FTSE 100-drugs giant.

To some, it may seem like a drop down the divisions, but the Cambridge-educated scientist-turned-businesswoman insists this is an “exciting opportunity” to make her mark on the UK life sciences sector.

That’s something she is clearly passionate about, as evidenced by her role as the president of the Association of the British Pharmaceutical Industry.

“I feel I can bring some leadership which will make a difference at Redx, where I think there’s some really strong science,” says Anson.

“We need to now relaunch the company and build it ready for growth so for me that’s an exciting opportunity.”

One of the first things on her to-do list is to get RXC004, the company’s lead drug, back into trials.

Porcupine inhibitors: Animal rescue?

The first patient in a Phase I/II trial was dosed back in February but Redx paused the study just over a month later, admitting that the dosing levels it had thought were right based on its pre-clinical research were actually too high.

Since then, it has been talking with regulators about lowering the dose and getting the trial back up and running again which it expects will happen in the first half of 2019.

“If we didn’t believe this drug had a window that could hit the target at a safe dose, we wouldn’t be going back into the clinic with it,” says Anson.

READ: Redx confirms RXC004 trial will resume early next year

Despite the temporary setback, Redx still has a lot of belief in RXC004, which is part of a niche, and potentially breakthrough group of cancer drugs called Porcupine inhibitors.

They work by dialling down the Porcupine protein, which is the control switch for the Wnt pathway – known to be heavily involved in cell growth and division.

“What you’re doing is readjusting the control switch (Porcupine) of one of the main pathways (Wnt) which controls the division of cells and thereby stopping the proliferation of cells (A.K.A cancer),” explains the new CEO.

Potential as a combination therapy

Now not all cancers are driven by the Wnt pathway, but the hope is that RXC004 will inhibit the growth of those which are.

Interestingly, there’s a growing bank of research that suggests Porcupine inhibitors may also be very effective in tandem with checkpoint inhibitors such as anti-PD-1, which lower or break cancer’s defence against the body’s immune system.

That’s why Anson and her team still plan to assess the drug in combination with a checkpoint inhibitor further down the line, something Swiss giant Novartis is doing with its Porcupine inhibitors.

Away from RXC004, Redx has a few other anti-cancer candidates, although they are still in pre-clinical development.

Fibrosis the other focus

Porcupine inhibitors aren’t just proving useful in the fight against cancer; more and more researchers are forming the opinion that they can be used to combat fibrosis.

The Wnt pathway is widely believed to be heavily involved in the tissue scarring process which is typical of idiopathic pulmonary fibrosis.

“The second leg of the company is the whole area of fibrosis, [which] is something we can really focus on. There are very few drugs in the market that actually tackle fibrosis, most of them are anti-inflammatory and don’t treat the fibrosis itself,” says Anson.

“Redx has some great agents against fibrosis so that’s another area of the business that I think we need to focus on developing alongside the 004 programme.”

READ: Redx Pharma's RXC006 compound shows fibrosis promise

One of those agents is RXC006, which has impressed in early pre-clinical trials.

Redx said the first batch of in-vivo data suggested the compound has “great potential” as a fibrosis treatment and it plans to kick off in-human clinical trials in 2020.

Fibrosis could prove to be a lucrative area as well, given that fibrosis can occur in many tissues within the body, affecting millions of people around the world. Some of the better-known examples are pulmonary fibrosis (lungs), cirrhosis (liver) and Crohn’s disease (intestine).

Sticking to what it knows

Those two areas will remain the focus for the foreseeable future as well, says Anson.

“We’re a small company and we really to make sure we deliver on the exciting assets that we’ve [already] got. Our priorities are to make sure we get RXC004 back into the clinic and to make sure that we accelerate the development of the fibrosis compounds.

“Behind that we have a series of programmes that we’re looking at that will build the next generation of assets but we’re not going to be looking outside of oncology and fibrosis.”

Tue, 17 Jul 2018 14:35:00 +1000
<![CDATA[RNS press release - Directorate Update and Grant of Options ]]> Mon, 04 Jun 2018 16:00:12 +1000 <![CDATA[RNS press release - Interim Results ]]> Wed, 30 May 2018 16:00:07 +1000 <![CDATA[News - Redx Pharma up as it confirms cancer drug clinical trial will re-start early next year ]]> Redx Pharma plc(LON:REDX) shares gained on Wednesday as the group confirmed it will restart early-stage clinical trials on its cancer drug after discussion with the regulator.

The phase I/IIa assessment of RXC004 was halted in March amid concerns the initial dosing was too high.

Crucially, there were no other 'off-target' side-effects, while the compound appeared to act in the way expected.

Following talks with the Medicines and Healthcare Regulatory Agency, work will restart early next year at a lower initial dose.

First-half results

The update was provided alongside first-half results, which showed Redx to be in a financially strong position with just over £10mln in the bank as at March 31.

The company, which recently unveiled senior AstraZeneca executive Lisa Anson  its new chief executive, has also managed to cut £7mln from costs on an annualised basis.

It meant that Redx's loss fell to £4.6mln in the six months from £10.7mln.

"I am pleased with the progress that Redx has made in the past six months," said chairman Iain Ross.  

"We have continued to advance our R&D programmes and achieved substantial cost savings across the business."

In mid-morning trading, Redx shares were 1.9% higher at 13.75p.

-- Adds share price --


Wed, 30 May 2018 07:55:00 +1000
<![CDATA[RNS press release - Share Purchase by Chairman ]]> Wed, 25 Apr 2018 19:57:23 +1000 <![CDATA[RNS press release - Second Price Monitoring Extn ]]> Wed, 25 Apr 2018 18:05:56 +1000 <![CDATA[RNS press release - Price Monitoring Extension ]]> Wed, 25 Apr 2018 18:00:39 +1000 <![CDATA[News - Redx Pharma shares soar 69% as executive chairman increases stake ]]> Redx Pharma Plc (LON:REDX) shares soared as the company announced that Iain Ross, its executive chairman, has today acquired 150,000 Redx oridinary shares at a price of 11p per share.

The drug developer said following this acquisition, Iain Ross will hold 600,000 ordinary shares in the company, representing 0.47% of the issued share capital.

Yesterday Redx Pharma's shares jumped 48% as the company announced the appointment of AstraZeneca PLC (LON:AZN) Lisa Anson as its new chief executive.

READ: Redx Pharma shares soar 48% after it recruits heavy hitter from drugs major AstraZeneca

In lunchtime trading company’s shares soared 69.2% to 16.5p.


Wed, 25 Apr 2018 12:00:00 +1000
<![CDATA[RNS press release - Redx Appoints Senior AstraZeneca Executive as CEO ]]> Tue, 24 Apr 2018 16:00:07 +1000 <![CDATA[News - Redx Pharma shares soar 48% after it recruits heavy hitter from drugs major AstraZeneca ]]> Shares in drug discovery group Redx Pharma PLC (LON:REDX) soared 48% after it pulled off a major coup with the appointment of a senior executive from drugs giant AstraZeneca PLC (LON:AZN) as its new chief executive.

She is 49-year-old Lisa Anson, who has been AZ’s UK president since 2012 and has worked for the company for more than two decades.

Anson, who has an MBA from the prestigious INSEAD business school and a first in natural sciences from Cambridge, joins Redx in June.

READ: Redx Pharma inks option and licence agreement for NBTI programme

Chairman Iain Ross, who took executive control following the departure of former CEO Neil Murray, will step back to a non-executive role, the company said in a statement.

Substantial biotech company 

He said: “Following the events of 2017 Lisa has been tasked by the Board to lead the re-launch of the company and to take the steps necessary to build a substantial biotech company built upon an innovative science base, selectively acquiring additional assets, if appropriate.

“Lisa is a consummate business professional, who brings a wealth of relevant experience from the international pharmaceutical and biotech sector. 

“I am confident that, as CEO, she is the right person to grow this company into a very exciting and meaningful entity that has the potential to create both important new medicines for patients and generate significant value for shareholders."

Those events referred to by Ross included suspension of trading in Redx shares and the sale of one of its leading assets.

Mentioned above, the shares reacted positively to the news, advancing 48% to 9.24p.

Best-in-class drugs 

Redx is focused on creating and developing first-, or potentially best-in-class drugs for cancer and fibrosis that address significant unmet medical needs.

Its flagship drug is RXC004, a porcupine inhibitor, a new and potentially breakthrough method of fighting cancer.

Porcupine inhibitors work by targeting cancer stems cells that can often lie dormant after traditional treatment and are associated with a recurrence of the illness.

The thinking goes that if you kill the stem cells, you have a chance of eradicating the disease completely.

Growing bank of research 

There is a growing bank of research that has found they may also be very effective in tandem with checkpoint inhibitors such as anti-PD-1, which lower or break cancer’s defence against the body’s immune system.

That’s why Redx has a twin track approach. RXC004 is currently undergoing a Phase I clinical trial as a single therapy targeted at gastric, biliary and pancreatic cancers.

At the same time, preparations are being made to for an early stage study of the drug in harness with an anti-PD-1 to combat melanoma.

The firm is also developing a porcupine drug for conditions such as non-alcoholic steatohepatitis hepatic fibrosis, or NASH for short.

It is the pick of a healthy early-stage programme that includes a tie-up with AstraZeneca, details of which are not currently in the public domain.

Tue, 24 Apr 2018 07:54:00 +1000
<![CDATA[RNS press release - Holding(s) in Company ]]> Fri, 13 Apr 2018 17:19:09 +1000 <![CDATA[RNS press release - Holding(s) in Company ]]> Thu, 12 Apr 2018 20:28:23 +1000 <![CDATA[RNS press release - RXC004 Clinical Trial Update ]]> Thu, 29 Mar 2018 17:00:07 +1100 <![CDATA[News - Redx Pharma calls a temporary halt to cancer trial to look at patient dosing ]]> Redx Pharma Plc (LON:REDX) said it was temporarily halting the early-stage clinical trial of a cancer drug candidate in order to amend the dose-escalation process to start at a lower initial threshold.

The delay to the phase I/IIa study of its Porcupine inhibitor, RXC004, is expected to be “several months” as it consults with regulators at the Medicines and Healthcare Products Regulatory Agency (MHRA) as to the next steps.

READ: Redx Pharma inks option and licence agreement for NBTI programme

"It is our current intention to propose a protocol amendment that enables dose-escalation to re-start at significantly lower dose levels,” said chief medical officer, Dr Andrew Saunders.

“This protocol amendment will be finalised with consultation with both the MHRA and principal investigators."

On dosing of the first patient in the trial, Redx said it encountered what it described as “clinically significant adverse events”.

The drug developer and its academic colleagues said this was possibly related to “RXC004 on-target effects and Wnt pathway inhibition”.

“Importantly, analysis of data from this first patient indicates that their systemic RXC004 exposure was significantly higher than that predicted from preclinical studies,” it added.

Chairman Iain Ross said the Redx team continued to believe RXC004 had potential.

“However, in drug development, safety of patients is the first priority and it is appropriate that the board and management has taken the decision to suspend recruitment of further patients to the trial until the company has consulted with the MHRA and agreed a plan to move forward.

“While we remain confident that we can address this issue, we currently estimate that that this suspension will lead to a delay of several months.

“The board continues to believe it has sufficient resources to continue to progress RXC004 and its broader portfolio of oncology and fibrosis assets. We intend to provide a further update in due course.”

Thu, 29 Mar 2018 07:41:00 +1100
<![CDATA[RNS press release - Redx and Deinove sign option and licence agreement ]]> Thu, 22 Mar 2018 18:00:04 +1100 <![CDATA[News - Redx Pharma inks option and licence agreement for NBTI programme ]]> In line with its strategy to focus in on its cancer and fibrosis pipeline, Redx Pharma Plc (AIM:REDX) has found a prospective partner for its next-generation anti-biotics.

For the drug developer has signed an option and licence agreement with Deinove of France that effectively outsources its novel bacterial topoisomerase inhibitor (NBTI) programme.

READ: Redx Pharma to present poster at American Association for Cancer Research Annual meeting

The nuts and bolts of the deal are as follows: Deinove has a nine-month period to assess the NBTI portfolio for further development.

Option deal 

Redx will receive a “fee and a payment” once the option has been triggered. Financial details were not disclosed.

Deinove, a biotech that develops high value drugs and other products from rare bacteria, will begin immediately confirmatory and profiling work with the compounds in the RedX programme.

Researchers are hoping to find a drug candidate to combat multi-drug resistant Gram negative bacteria.

Rise of super-bugs

The rise of super-bugs that are immune to traditional antibiotics is now generally regarded as a pressing threat and certainly one that developed economies and the World Health Organisation are taking seriously.

RedX chairman Iain Ross said: "We are very pleased to have partnered our NBTI programme with Deinove, who are committed to the development of anti-infectives and whose team has a proven track record of bringing products to market.

“With their experience in this area, we hope that they can successfully progress our NBTI programme towards the clinic.

“We had previously indicated our commitment to progressing anti-infectives research through a collaboration in the near term and are delighted to be making this announcement on schedule."

Thu, 22 Mar 2018 08:09:00 +1100
<![CDATA[RNS press release - Poster Presentation at AACR Annual Meeting ]]> Thu, 15 Mar 2018 18:00:08 +1100 <![CDATA[News - Redx Pharma to present poster at American Association for Cancer Research Annual meeting ]]> Redx Pharma Plc (LON:REDX) has announced that its abstract has been accepted for presentation as a poster at the American Association for Cancer Research Annual meeting in Chicago in April.

The AIM-listed drug development company said the poster relates to its lead candidate, RXC004, a potent and selective, orally bioavailable porcupine inhibitor, which is currently being investigated in a phase 1/2a clinical trial in patients with hard to treat cancers.

READ: Redx Pharma starts dosing on its RXC004 cancer study

It is expected that initial data from the 1a segment of this trial will be available in the second half of 2018.

Richard Armer, Redx Pharma's chief scientific officer said: “We are delighted that our abstract has been accepted at such a high profile conference.”

He added: “We are excited by the potential of RXC004 as a treatment for challenging cancers and look forward to announcing the first data from our clinical development programme with this compound.”

Thu, 15 Mar 2018 07:31:00 +1100
<![CDATA[RNS press release - Result of AGM ]]> Wed, 07 Mar 2018 03:33:33 +1100 <![CDATA[RNS press release - Posting of Annual Accounts & AGM notice ]]> Mon, 12 Feb 2018 21:23:21 +1100 <![CDATA[RNS press release - First Patient Dosed in Phase 1/2a Trial of RXC004 ]]> Tue, 06 Feb 2018 18:00:02 +1100 <![CDATA[News - Redx Pharma starts dosing on its RXC004 cancer study ]]> Redx Pharma Plc (LON:REDX) has commenced its Phase 1/2a cancer study for the Porcupine inhibitor RXC004.

The company said the first patient has now been dosed at The Christie hospital in Manchester.

READ: Redx Pharma gets UK go-ahead for first clinical trial of cancer treatment

Redx’s RXC004 is a novel, oral, potent small molecule Porcupine inhibitor, which targets the Wnt pathway, an embryonic signalling pathway that is implicated in the maintenance of cancer stem cells in multiple cancer types; this pathway is associated with tumorigenesis, metastasis, recurrence and resistance in cancer.

Once the dose-finding Phase 1 element of the study is completed, the selected dose will then be used as a monotherapy in a larger number of patients with difficult to treat cancers (Phase 2a). In addition, the company will look to explore the potential of RXC004 in combination with a PD-1 checkpoint inhibitor following the completion of the safety and tolerability phase of this first in man clinical trial.

As previously mentioned, Redx expects initial data from the 1a segment of the trial in the second half of this year.

READ: Redx Pharma appoints chief medical officer who will oversee launch of phase I clinical trial of new cancer drug

"We are very excited by the potential of RXC004 to make a major difference in cancer treatment and intend to progress RXC004 initially as a monotherapy and thereafter in combination with a (PD-1) checkpoint inhibitor through clinical development. We believe that RXC004 has great potential to treat some very challenging cancers that currently have very poor prognosis and we look forward to updating the market on our progress," said Ian Ross, Redx’s chairman.

Tue, 06 Feb 2018 08:14:00 +1100
<![CDATA[RNS press release - Appointment of Chief Medical Officer ]]> Mon, 22 Jan 2018 18:00:03 +1100 <![CDATA[News - Redx Pharma appoints chief medical officer who will oversee launch of phase I clinical trial of new cancer drug ]]> Redx Pharma Plc (LON:REDX) has appointed a chief medical officer ahead of the imminent launch of phase I clinical trials of its lead drug.

Dr Andrew Saunders has 25 years in the cancer field and was recruited from Lytix Biopharma, a Norwegian immuno-oncology firm, where he held the same role.

READ: Redx Pharma reborn with lower cost base and multiple shots on goal

He will work with the research and development team at Redx, “fronting” the clinical development of RXC004.

This is a potentially potent small molecule drug called a porcupine inhibitor that targets Wnt pathway.

Chairman Iain Ross said he was “very pleased” to announce Saunders’ appointment.

“He brings to the company a wealth of relevant experience and expertise in the clinical development of oncology drugs,” Ross explained.

“This will be invaluable as the company transforms into a clinical stage company with the anticipated commencement of the first phase I study on lead compound RXC004 in the coming weeks.

"We are very excited by the potential of RXC004 to make a major difference in cancer treatment.

“We intend to progress RXC004 in the clinic both as a monotherapy and in combination with a checkpoint inhibitor. Therefore, we envisage that Andrew's recent experience in immuno-oncology combination trials will be particularly pertinent to the design and execution of future clinical trials with RXC004."

Porcupine inhibitors such as RXC004 are a new and potentially breakthrough method of fighting the killer disease.

READ: Redx reshuffles board and clarifies new strategy ahead of rejoining junior market

They work by targeting cancer stems cells that can often lie dormant after traditional treatment and are associated with a recurrence of the illness. Kill the stem cells and you have a chance of eradicating the disease completely.

Clinical trials of the new Redx drug commence in the “coming weeks”.

Mon, 22 Jan 2018 08:01:00 +1100
<![CDATA[RNS press release - Holding(s) in Company ]]> Thu, 28 Dec 2017 22:28:00 +1100